Navigation Links
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer

PHILLIPSBURG, N.J., May 21 /PRNewswire/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) announced today it has received Federal Trade Commission approval under the Hart-Scott Rodino (HSR) Act, clearing AVANT's proposal to award Pfizer (NYSE: PFE) exclusive rights to CDX-110, an investigational vaccine currently under development.

On April 16, 2008, Pfizer, Inc. and Celldex announced that they entered into an agreement under which Pfizer would be granted an exclusive worldwide license to CDX-110, currently being evaluated in a Phase 2 study for the treatment of glioblastoma multiforme (GBM). The agreement also gives Pfizer exclusive rights to the use of this vaccine targeting the tumor specific EGFR mutant EGFRvIII in other potential indications.

About CDX-110

CDX-110 is designed to induce or enhance the body's immune responses against EGFRvIII resulting in destruction of tumor cells that express the variant receptor. Single arm Phase 2 clinical trials of CDX-110 in combination with the current standard treatment for patients with GBM have been conducted. Updated clinical data will be released at the American Society for Clinical Oncology Meeting in Chicago on June 2, 2008. A randomized Phase 2 trial is currently enrolling at 24 sites across the United States.

About AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics and Celldex Therapeutics combined during the first quarter of 2008. AVANT is a Nasdaq-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel "targeted immunization" approach. In addition, AVANT is exploiting its access to proprietary human antibody technology for development of therapeutic monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of products in varying stages of development. Identification of the potential of EGFRvIII in cancer diagnosis, prevention and therapy was based on the collaborative efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Application of this discovery toward the development of the CDX-110 vaccine was further advanced by Dr. John Sampson and his colleagues at the Duke University Brain Tumor Center in collaboration with Dr. Amy Heimberger at the MD Anderson Cancer Center. AVANT has several other product candidates in its development pipeline including:
-- CDX-1307, a product based on its proprietary APC Targeting

Technology(TM), which is in two Phase 1 clinical trials for patients

with advanced pancreatic, bladder, breast and colon cancer;

-- TP10, a complement inhibitor, in development for transplantation and

other indications; and

-- Three candidates based on oral, rapidly-protecting, single-dose and

temperature-stable vaccine technology, including combination vaccines

for travellers, the military and global health needs.

AVANT has three commercialized products, including Rotarix(R) (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through its web site

AVANT Immunotherapeutics, Inc.

Anthony S. Marucci, 781-433-0771

Interim President and CEO

BMC Communications

Marissa Nelson

(212) 477-9007 x21

SOURCE Celldex Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avantium and BP Extend Strategic Partnership
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... Colorado (PRWEB) , ... October 09, 2015 , ... ... Station, one of the oldest and largest recreational dispensaries in Colorado, says the ... cannabis business is growing rapidly and maturing into a legitimate industry. , ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... assisted living placement counseling, recently opened its newest office in Maryland – its ... care industry with a background as a project management technology consultant to many ...
(Date:10/9/2015)... ... ... Smanos was featured on NewsWatch as part of its monthly Tech Report, which features ... and special reporter for NewsWatch, conducted the review and shared with viewers how this ... age it’s more important than ever to keep homes and dorms safe and protected. ...
Breaking Medicine News(10 mins):
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... , WHAT: YEAR-IN-PREVIEW WEBINAR ... Wednesday, January 7, 2009 11:00 AM (U.S. Eastern Time) ... ENROLL: Please use the link below to register ... Millennium Research Group (MRG) complimentary webinar identifying the top 10 ...
... will be the subject of a policy forum sponsored ... January 13, 2009, from 3:00 p.m. until 4:30 p.m. ... Suites Resort, 5001 N. Scottsdale Road, Scottsdale, Arizona. This ... explore the relationship between health insurance coverage and access ...
... Mo., Jan. 5 The recent tragic death of Jett ... which he was diagnosed in early childhood. Kawasaki disease is ... the age of five. The disease occurs more often in ... and Korean descent. Although most children diagnosed with Kawasaki recover ...
... AUGUSTA, Ga. Just days after the first retinal ... start committing suicide and researchers believe their death may ... infection. , Understanding the cell death may also provide ... retina responds to assault, whether by infection or a ...
... WASHINGTON, Jan. 5 Despite a deepening recession, only ... raise less money this year than in 2008 said ... services for the poor and underinsured, according to a ... Philanthropy ( ).The overwhelming majority of AHP members ...
Cached Medicine News:
(Date:10/9/2015)... , October 9, 2015 ... major players. --> India ... --> announces addition of 3 divalproex ... 2020 forecasts for global markets as well as ... along with analysis of major players. ...
(Date:10/9/2015)... 9, 2015  The Centers for Disease Control ... and Zoonotic Infectious Diseases, Office of Advanced Molecular ... a research collaboration to evaluate the performance of ... this research collaboration is to evaluate the utility ... health and infectious disease applications. This collaboration will ...
(Date:10/9/2015)... ClinicalKey Nursing debuts at ...   Elsevier , a world-leading provider of ... ClinicalKey for Nursing , a new clinical reference platform ... unique needs of nursing professionals. Attendees of the ANCC ... Oct. 7-9, will have the opportunity to demo ClinicalKey Nursing ...
Breaking Medicine Technology:
... plan for various study outcomes, MEXICO CITY, Aug. ... a new report, Anticipating the Results of PrEP,Trials, calling ... and advocates to prepare for initial,results - expected as ... drugs being tested for HIV prevention, known as PrEP ...
... is pleased,to announce the dosing of the first patient ... of AEG35156, a second generation antisense,therapeutic targeting XIAP, a ... The study, made possible, in part, by funding from ... Multicenter, Open-Label Study,of the X- Linked Inhibitor of Apoptosis ...
Cached Medicine Technology:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: